Breast cancer (BC) is the most prevalent cancer among women worldwide and the major cause of cancer-associated mortalities. Commonly, the primary treatment used for cancer patients is chemotherapy. Doxorubicin (DOX) is considered an anthracycline derivative and conversant chemotherapeutic agent and one of the most influential chemotherapeutic drugs. In addition, it is among the most frequently applied drugs for BC. According to recent reports, RNA is crucial for the development of several cancers and illnesses. Long non-coding RNAs (lncRNAs) exert a particularly vital role in this respect. The current reviews demonstrate that lncRNAs can function as oncogenic and tumor suppressor and contribute to cancer development and progression. Our study addressed nuclear-enriched abundant transcript 1 (NEAT1) and the effect of DOX contributing to the regulation of miR410 by NEAT1. After receiving DOX treatment, it was discovered that NEAT1 expression levels were practically decreased in human BC cells, including MDA-MB231 and MCF-7. As expected, further expression than cancer cell lines were detected in normal mammary epithelial cell MCF-10A. Simultaneously, neither the dose administration levels nor the cell lines showed any changes in the expression of miR410. Alterations in the expression level were measured by the quantitative real-time polymerase chain reaction analyzes. This indicates that DOX may affect BC lines via NEAT1, and miR410 is ineffective in this pathway. Our data confirmed that the contribution of NEAT1 in DOX treatment. Accordingly, it can be provided as a biomarker in the diagnosis and treatment of BC.